Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells Ng, P. P., Mobasher, M., Yeung, K. S., Hotson, A. N., Hill, C. M., Madriaga, A., Dao-Pick, T. P., Verner, E., Radeski, D., Khodadoust, M. S., Kim, Y. H., Miller, R. A., Buggy, J. J., Janc, J. W. AMER SOC HEMATOLOGY. 2019

View details for DOI 10.1182/blood-2019-127338

View details for Web of Science ID 000577160402124